8 research outputs found
Array-CGH characterization and genotype-phenotype analysis in a patient with a ring chromosome 6
Diagnosis of Noonan syndrome and related disorders using target next generation sequencing
Extensive Molecular Analysis Suggested the Strong Genetic Heterogeneity of Idiopathic Chronic Pancreatitis
Abstract Genetic features of chronic pancreatitis (CP) have been investigated extensively, mainly by testing genes associated to the trypsinogen activation pathway. However, different molecular pathways involving other genes may be implicated in CP pathogenesis. A total of 80 patients with idiopathic chronic pancreatitis (ICP) were investigated using a Next-Generation Sequencing (NGS) approach with a panel of 70 genes related to six different pancreatic pathways: premature activation of trypsinogen, modifier genes of cystic fibrosis phenotype, pancreatic secretion and ion homeostasis, calcium signaling and zymogen granules (ZG) exocytosis, autophagy and autoimmune pancreatitis-related genes. We detected mutations in 34 out of 70 genes examined; of the 80 patients, 64 (80.0%) were positive for mutations in one or more genes and 16 (20.0%) had no mutations. Mutations in CFTR were detected in 32 of the 80 patients (40.0%) and 22 of them exhibited at least one mutation in genes of other pancreatic pathways. Of the remaining 48 patients, 13/80 (16.3%) had mutations in genes involved in premature activation of trypsinogen and 19/80 (23.8%) had mutations only in genes of the other pathways: 38 (59.3%) of the 64 patients positive for mutations showed variants in two or more genes. Our data, although to be extended with functional analysis of novel mutations, suggest a high rate of genetic heterogeneity in CP and that trans-heterozygosity may predispose to the ICP phenotype
Relationship between CFTR and CTRC Variants and the Clinical Phenotype in Late-Onset Cystic Fibrosis Disease with Chronic Pancreatitis
Comparison of Mobile Stroke Unit With Usual Care for Acute Ischemic Stroke Management A Systematic Review and Meta-analysis
IMPORTANCE So far, uncertainty remains as to whether there is sufficient
cumulative evidence that mobile stroke unit (MSU; specialized ambulance
equipped with computed tomography scanner, point-of-care laboratory, and
neurological expertise) use leads to better functional outcomes compared
with usual care.
OBJECTIVE To determine with a systematic review and meta-analysis of the
literature whether MSU use is associated with better functional outcomes
in patients with acute ischemic stroke (AIS).
DATA SOURCES MEDLINE, Cochrane Library, and Embase from 1960 to 2021.
STUDY SELECTION Studies comparing MSU deployment and usual care for
patients with suspected stroke were eligible for analysis, excluding
case series and case-control studies.
DATA EXTRACTION AND SYNTHESIS Independent data extraction by 2
observers, following the PRISMA and MOOSE reporting guidelines. The risk
of bias in each study was determined using the ROBINS-1 and RoB2 tools.
In the case of articles with partially overlapping study populations,
unpublished disentangled results were obtained. Data were pooled in
random-effects meta-analyses.
MAIN OUTCOMES AND MEASURES The primary outcome was excellent outcome as
measured with the modified Rankin Scale (mRS; score of 0 to 1 at 90
days).
RESULTS Compared with usual care, MSU use was associated with excellent
outcome (adjusted odds ratio [OR]. 1.64; 95% CI, 1.27-2.13; P < .001;
5 studies; n = 3228). reduced disability over the full range of the mRS
(adjusted common OR, 1.39; 95% CI, 1.14 1.70; P = .001; 3 studies; n =
1563), good outcome (mRS score of 0 to 2: crude OR, 1.25; 95% CI, 1.09
1.44; P = .001; 6 studies; n = 3266). shorter onset-to-intravenous
thrombolysis (IVT) times (median reduction, 31 minutes [95% CI, 23
39]; P < .001; 13 studies; n = 3322), delivery of IVT (crude OR, 1.83;
95% CI, 1.58 2.12; P < .001; 7 studies; n = 4790), and IVT within 60
minutes of symptom onset (crude OR, 7.71; 95% CI, 4.17 14.25; P < .001;
8 studies; n = 3351). MSU use was not associated with an increased risk
of all-cause mortality at 7 days or at 90 days or with higher
proportions of symptomatic intracranial hemorrhage after IVT.
CONCLUSIONS AND RELEVANCE Compared with usual care, MSU use was
associated with an approximately 65% increase in the odds of excellent
outcome and a 30-minute reduction in onset-to-IVT times, without safety
concerns. These results should help guideline writing committees and
policy makers
Intravenous thrombolysis or endovascular therapy for acute ischemic stroke associated with cervical internal carotid artery occlusion: the ICARO-3 study
The aim of the ICARO-3 study was to evaluate whether intra-arterial treatment, compared to intravenous thrombolysis, increases the rate of favourable functional outcome at 3 months in acute ischemic stroke and extracranial ICA occlusion. ICARO-3 was a non-randomized therapeutic trial that performed a non-blind assessment of outcomes using retrospective data collected prospectively from 37 centres in 7 countries. Patients treated with endovascular treatment within 6 h from stroke onset (cases) were matched with patients treated with intravenous thrombolysis within 4.5 h from symptom onset (controls). Patients receiving either intravenous or endovascular therapy were included among the cases. The efficacy outcome was disability at 90 days assessed by the modified Rankin Scale (mRS), dichotomized as favourable (score of 0-2) or unfavourable (score of 3-6). Safety outcomes were death and any intracranial bleeding. Included in the analysis were 324 cases and 324 controls: 105 cases (32.4 %) had a favourable outcome as compared with 89 controls (27.4 %) [adjusted odds ratio (OR) 1.25, 95 % confidence interval (CI) 0.88-1.79, p = 0.1]. In the adjusted analysis, treatment with intra-arterial procedures was significantly associated with a reduction of mortality (OR 0.61, 95 % CI 0.40-0.93, p = 0.022). The rates of patients with severe disability or death (mRS 5-6) were similar in cases and controls (30.5 versus 32.4 %, p = 0.67). For the ordinal analysis, adjusted for age, sex, NIHSS, presence of diabetes mellitus and atrial fibrillation, the common odds ratio was 1.15 (95 % IC 0.86-1.54), p = 0.33. There were more cases of intracranial bleeding (37.0 versus 17.3 %, p = 0.0001) in the intra-arterial procedure group than in the intravenous group. After the exclusion of the 135 cases treated with the combination of I.V. thrombolysis and I.A. procedures, 67/189 of those treated with I.A. procedures (35.3 %) had a favourable outcome, compared to 89/324 of those treated with I.V. thrombolysis (27.4 %) (adjusted OR 1.75, 95 % CI 1.00-3.03, p = 0.05). Endovascular treatment of patients with acute ICA occlusion did not result in a better functional outcome than treatment with intravenous thrombolysis, but was associated with a higher rate of intracranial bleeding. Overall mortality was significantly reduced in patients treated with endovascular treatment but the rates of patients with severe disability or death were similar. When excluding all patients treated with the combination of I.V. thrombolysis and I.A. procedures, a potential benefit of I.A. treatment alone compared to I.V. thrombolysis was observed